BMS' Opdivo wins speedy FDA approval in lung cancer
This article was originally published in Scrip
Executive Summary
Just days after Bristol-Myers Squibb revealed it had won a priority review from the FDA for the firm's application for Opdivo (nivolumab) as a treatment for patients with advanced squamous non-small cell lung cancer (NSCLC) after prior therapy, regulators made a stunning announcement that the agency had granted approval.